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Abstract
Background: Influenza virus (IV) infections are a major threat to human welfare and animal health
worldwide. Anti-viral therapy includes vaccines and a few anti-viral drugs. However vaccines are
not always available in time, as demonstrated by the emergence of the new 2009 H1N1-type
pandemic strain of swine origin (S-OIV) in April 2009, and the acquisition of resistance to
neuraminidase inhibitors such as Tamiflu® (oseltamivir) is a potential problem. Therefore the
prospects for the control of IV by existing anti-viral drugs are limited. As an alternative approach
to the common anti-virals we studied in more detail a commercial standardized extract of the
widely used herb Echinacea purpurea (Echinaforce®, EF) in order to elucidate the nature of its anti-
IV activity.
Results: Human H1N1-type IV, highly pathogenic avian IV (HPAIV) of the H5- and H7-types, as
well as swine origin IV (S-OIV, H1N1), were all inactivated in cell culture assays by the EF
preparation at concentrations ranging from the recommended dose for oral consumption to
several orders of magnitude lower. Detailed studies with the H5N1 HPAIV strain indicated that
direct contact between EF and virus was required, prior to infection, in order to obtain maximum
inhibition in virus replication. Hemagglutination assays showed that the extract inhibited the
receptor binding activity of the virus, suggesting that the extract interferes with the viral entry into
cells. In sequential passage studies under treatment in cell culture with the H5N1 virus no EF-
resistant variants emerged, in contrast to Tamiflu®, which produced resistant viruses upon
passaging. Furthermore, the Tamiflu®-resistant virus was just as susceptible to EF as the wild type
virus.
Conclusion:  As a result of these investigations, we believe that this standard Echinacea
preparation, used at the recommended dose for oral consumption, could be a useful, readily
available and affordable addition to existing control options for IV replication and dissemination.
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Background
Influenza viruses (IV) continue to cause problems glo-
bally in humans and their livestock, particularly poultry
and pigs, as a consequence of antigenic drift and shift,
resulting frequently and unpredictably in novel mutant
and re-assortant strains, some of which acquire the ability
to cross species barriers and become pathogenic in their
new hosts [1]. Prospects for the emergence of pandemic
strains of swine and avian origin have been discussed in
several recent reports [2,3]. Some of the highly pathogenic
avian IV (HPAIV) strains, in particular H5N1, have occa-
sionally infected humans and pose a severe threat because
of their high pathogenicity, with mortality rates exceeding
60% [4,5].
The practicality and efficacy of control by timely vaccina-
tion has been questioned [1,6,7], and potential control of
IV by synthetic anti-viral chemicals has usually been
thwarted by the inevitable emergence of resistant strains,
a situation that has been documented in the case of the
M2 ion-channel inhibitors, such as adamantane deriva-
tives, and the neuraminidase inhibitors such as oseltami-
vir and zanamivir [8,9]. Virus-strain specificity is another
limitation in the use of these inhibitors.
Alternative approaches to therapy that overcome these
obstacles are urgently needed and have been suggested.
These include manipulation of specific signaling path-
ways known to be involved in virus replication [10,11]. As
such, the Raf/MEK/ERK-signal transduction cascade and
activation of the transcription factor NF-κB were shown to
be essential for efficient nuclear export of the viral ribonu-
cleoprotein (RNP) complexes. They have proven to be
highly interesting targets, as their inhibition significantly
reduces virus replication without emergence of resistant
variants in vitro and in vivo [12-15]. Another approach is
the use of broad-spectrum and chemically-standardized
anti-IV herbal extracts and compounds with demon-
strated efficacy in vitro [16-19]. These could conceivably
afford a more generalized inhibition of all virus strains,
either by virtue of inactivating the virus directly or by
interfering with one or more essential stages in virus rep-
lication or dissemination. Furthermore anti-viral herbal
extracts frequently exhibit multiple bioactivities [20], and
this could enable their use at relatively low doses of the
active compounds, possibly acting in synergy, while at the
same time providing a relatively safe "drug" with few side
effects. Needless to say, acquisition of resistance to herbal
compounds is also a potential problem; consequently this
would need to be evaluated, although if multiple bioac-
tive compounds were involved, this would substantially
reduce the risk of resistant viruses emerging.
We recently reported the anti-viral properties of a stand-
ardized preparation of Echinacea purpurea (Echinaforce®,
EF), which has become a very popular herbal "remedy"
for the symptoms of "colds and flu". In addition to pos-
sessing potent virucidal activity against several membrane
containing viruses, including H3N2-type IV, at the recom-
mended dose for oral consumption, the preparation also
effectively reversed virus-induced pro-inflammatory
responses in cultured epithelial cells [21]. Some Echina-
cea-derived preparations also possess selective anti-bacte-
rial and immune modulation activities that might also
contribute to their beneficial properties [22,23]. However,
our studies also indicated that anti-viral and cytokine-
inhibitory properties vary widely among different Echina-
cea species and components [24-26]; thus it is important
to carry out research on Echinacea preparations that have
been standardized and chemically characterized.
The objective of the present study was to investigate the
anti-IV activity in more detail, and to elucidate possible
mechanisms of action on a variety of IV strains (human
and avian), with emphasis on a human isolate of the
H5N1-type HPAIV, and to evaluate the potential for emer-
gence of resistant strains, in comparison with oseltamivir
(Tamiflu®).
Results
Echinaforce® (EF) and Virus Concentration
We reported previously that at concentrations up to 1.6
mg/ml (dry mass/vol, the recommended oral dose) the EF
extract showed no apparent cytotoxic effects, according to
trypan blue staining, MTT assays, or microscopic examina-
tion [[21], data not shown]. However at concentrations of
>1.6  μg/ml  ≥99% inactivation of H3N2-type IV was
achieved (Table 1). The degree of inactivation depended
on the virus dose, as might be expected (Fig. 1). MIC100
values increased from 0.32 μg/ml for 102 PFU/ml virus, up
to 7.5 μg/ml for 105 PFU/ml.
In order to exclude the possibility that the virucidal effect
might be subtype specific or related only to human IV, we
analyzed the effect of EF in non toxic concentrations on a
human isolate of a H5N1-type HPAIV (KAN-1). Virus
yield reduction assays were carried out with KAN-1, which
had been pre-incubated with various concentrations of
EF, from 0.1 to 50 μg/ml (Fig. 2). At the highest concen-
tration the yield was reduced by more than 3 log10. Fur-
thermore we tested the inhibitory effect of EF on human
H1N1-type (PR8) and a H7-type HPAIV (FPV) and
obtained comparable results (data not shown), indicating
that EF affects not only human IV (H3N2, H1N1) but also
both types (H5, H7) of HPAIV (data not shown).
Time of addition of Echinaforce®
All the IV strains tested, the human pathogenic Victoria
(H3N2), PR8 (H1N1), S-OIV (H1N1), and the avian
strains KAN-1 (H5N1) and FPV (H7N7) were susceptibleVirology Journal 2009, 6:197 http://www.virologyj.com/content/6/1/197
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to the EF, but only as a result of direct contact. Pre-incuba-
tion of cells with extract, followed by virus infection, or
post-exposure of the infected cells to EF, inhibited virus
replication to a lesser extent (data not shown). To investi-
gate this in more detail, several experiments were per-
formed with KAN-1 to determine the effect of adding EF
at different times relative to virus infection of the cells.
Complete inhibition was achieved by incubating KAN-1
and EF together before adding to the cells (Fig 3, lanes 3,
4, and 6). However other combinations of pre- and post-
exposure to EF (lanes 2, 5, and 7) resulted in only partial
reduction in virus production, compared to untreated
(lane 1). These results suggest that EF was acting either
directly on the virus or at a very early stage in the replica-
tion cycle. It is noteworthy to mention, that removal of EF
containing medium 6.5 hours p.i. and further incubation
in normal medium for 1.5 hours in order to prevent an
exposure of newly formed virions to EF prior to titration,
did not change this result.
Intra-cellular RNP localization
Next, the production and intra-cellular localization of
viral RNP were determined by immunofluorescence, in
MDCK cells infected with KAN-1, with and without EF
treatment (Fig 4). In normally infected cells (- EF), the
nucleocapsid protein (NP, green), which is the main com-
ponent of the RNPs, appeared initially in the nucleus (6
hours) followed by migration to the cytoplasm (8 hours).
The same pattern was seen in EF-treated cells infected with
untreated virus (cells + EF), and in cells exposed to EF after
infection (EF p.i.). However, when cells were infected with
EF-treated virus (virus + EF), the overall number of posi-
tive cells was significantly reduced. Nevertheless, the
amount and the localization of RNPs detected in cells
infected with pre-treated IV was the same as for untreated
cells infected with untreated virus. It should be noted that
the treatment of infected cells at different time points p.i.
did not affect the number of cells positive for NP staining
(data not shown). These results suggest that EF affects a
very early stage before replication, but once the virus has
entered the cells its replication and spread are not affected.
Interaction of Echinaforce® with Viral HA
The first step in entry of IV into cells depends on the inter-
action between the viral HA and a specific cellular sialic
MIC depends on the viral dose Figure 1
MIC depends on the viral dose. Increasing amounts of IV 
(Victoria, H3N2) were used to determine the MIC100 of EF. 
Serial dilutions of EF, in quadruplicate, were incubated with 
the amounts of IV indicated (102, 103, 104, 105 PFU), and 
transferred to cells for CPE-endpoint determination, as 
described in Materials and Methods section. The MIC100 (μg/
ml) is the concentration of EF that leads to complete preven-
tion of CPE.
Table 1: Anti-influenza virus (H3N2) effect of EF
EF dilution
(μg/ml)
Virus titer
(PFU, % of control)
1:30 (53.3) < 0.1
1:102 (16) < 0.1
1: 103 (1.6) < 0.1
1: 104 (0.16) 1.0 ± 0
1: 105 (0.016) 110 ± 7.8
Aliquots of H3N2 virus, containing 105 PFU/ml, were incubated at 
22°C for 60 min with the indicated concentrations of EF, and assayed 
for remaining PFU/ml
EF acts in a dose dependent manner Figure 2
EF acts in a dose dependent manner. H5N1 HPAIV 
(MOI = 0.001) and MDCK cells were pre-incubated with EF 
at the indicated concentrations 1 hour prior to infection. 
Infected cells were then incubated in media with EF at the 
appropriate concentrations for 24 hours and the infectious 
titer was determined (FFU/ml). The experiment was per-
formed in triplicate, and titrations in duplicate.
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acid containing receptor. If EF could inhibit this interac-
tion by binding to the HA, then entry of virus might be
prevented. Receptor binding of functional HA can be
measured by its ability to agglutinate chicken erythro-
cytes, which can be easily enumerated visually. Direct
interaction between virus and EF was therefore examined
by inspecting viral hemagglutination (HA) activity in the
presence and absence of EF. Results for the pandemic S-
OIV (H1N1) and two HPAIV (H5, H7) are shown in Table
2. EF inhibited HA activity for all 3 virus strains, in a con-
centration and time-dependent manner. The same con-
centrations of EF without virus showed no
hemagglutination, as expected (data not shown). In addi-
tion there was no visual evidence of erythrocyte lysis in
any of the reactions. Therefore the inhibition in HA activ-
ity was due to an interference by EF. As this is effective
against different human and avian strains, EF might exert
an unspecific effect on IV replication by interfering with
viral receptor binding and entry.
Lack of Resistance to Echinaforce®
Treatment with currently available anti-influenza drugs
directly targeting the virus has the drawback that, due to
the high mutation rate of IV, resistant strains will inevita-
bly arise. This has been shown for neuraminidase inhibi-
tors like Tamiflu® in regard to seasonal IV, H5N1 HPAIV
and in recent reports for the pandemic S-OIV
[2,3,9,27,28]. Therefore, any competitive alternative
should have the advantage of preventing emergence of
resistant IV variants [11]. This might be different for a sub-
Pre-treatment of IV with EF is most effective Figure 3
Pre-treatment of IV with EF is most effective. H5N1 HPAIV (MOI = 1) and MDCK cells were treated with EF (50 μg/ml) 
as indicated. Infected cells were then incubated in medium with or without EF for 8 and 24 hours and the infectious titer was 
determined (FFU/ml). The experiment was performed in triplicate, and titrations in duplicate.
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stance that unspecifically blocks virus activity. The possi-
bility of emergence of EF-resistant virus was evaluated by
comparing relative H5N1 virus yields in the presence and
absence of EF, or Tamiflu®, during consecutive passages
through cell cultures. Results are shown in Fig 5. After one
round of replication virus yields were substantially
reduced by 50 μg/ml EF or 2 μM Tamiflu®. However in
rounds 2 and 3 the yields in the presence of Tamiflu® were
similar to controls, indicative of emergence of resistant
virus variants, whereas in the presence of EF yields contin-
ually remained low, indicating lack of EF-resistant virus.
To determine if Tamiflu®-resistant virus remained sensi-
tive to EF, the growth of Tamiflu®-resistant virus (pro-
duced in the above experiments) was tested in the
presence and absence of EF. EF (50 μg/ml) reduced the
yield of Tamiflu®-resistant virus by more than 3 log10 viral
FFU, similar to that of standard virus (data not shown).
Discussion
These results have shown that Echinaforce® (EF), a stand-
ardized Echinacea purpurea extract, has potent anti-viral
activity against all the IV strains tested, namely human
Victoria (H3N2) and PR8 (H1N1), avian strains KAN-1
(H5N1) and FPV (H7N7), and the pandemic S-OIV
(H1N1). Concentrations ranging from 1.6 mg/ml, the rec-
ommended dose for oral consumption, to as little as 1.6
μg/ml of the extract, a 1:1000 dilution, could inactivate
more than 99% of virus infectivity, and treated virus gave
rise to markedly reduced yields of virus in cell culture.
However, direct contact between virus and EF was
required for this inhibitory effect, since pre-treatment of
cells before virus infection, or exposure of cells p.i. to EF,
led to substantially less inhibition, indicating that the
anti-viral effect was manifest at a very early stage in the
infection process. This was then confirmed by the use of
hemagglutination assays, which clearly showed that EF
inhibited HA activity and consequently would block entry
of treated virus into the cells. Nevertheless, the mecha-
nism of this inhibition needs to be studied in more detail.
The general inhibition of EF against the different virus
strains constitutes a significant advantage over other strain
specific anti-virals, such as adamantanes [8,9]. Further-
more, the lack of emergence of EF-resistant viruses during
sequential passage is a significant advantage over Tami-
flu®, which under similar culture conditions readily
allowed resistant virus strains to develop. In addition the
Tamiflu®-resistant virus was still very sensitive to EF. These
results indicate that EF could be helpful in IV control, and
would be complemented by the known ability of EF to
counteract pro-inflammatory cytokine and chemokine
induction caused by IV and other viruses, as well as the
selective anti-bacterial activities of Echinacea extracts [23].
Thus EF could play a multi-functional role during IV infec-
tions.
Intra-cellular RNP production and localization is not affected  by EF Figure 4
Intra-cellular RNP production and localization is not 
affected by EF. H5N1 HPAIV (MOI = 1) and MDCK cells 
were either left untreated or were treated with EF as fol-
lows: (-) EF, normal infection with no EF treatment; (EF p.i.), 
infected cells treated with EF (50 μg/ml) after infection; virus 
(+) EF, virus pretreated with EF (50 μg/ml); cells (+) EF, cells 
pretreated with EF (50 μg/ml), and infected with untreated 
virus. Infected cells were then incubated in medium with or 
without EF for 6 and 8 hours and the intra-cellular amount 
and localization of viral RNPs (green), as well as the nuclei 
(blue), were detected by immunofluorescence.
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Table 2: Interaction of EF with viral HA
μg/ml EF 1 hour μg/ml EF 4 hours
IV 
strain
Pos. 
Ctrl.
Neg. 
Ctrl.
50 100 200 400 800 50 100 200 400 800
S - O I V  ( H 1 N 1 ) + - - ---- - ----
K A N - 1  ( H 5 N 1 ) + -+ + +-- - ----
F P V  ( H 7 N 7 ) + -+ + +-- - ----
+: indicates hemagglutinin activity (agglutination of erythrocytes)
-: indicates no hemagglutin activity. Ctrl, controlVirology Journal 2009, 6:197 http://www.virologyj.com/content/6/1/197
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The Echinaforce® extract contains known concentrations
of potentially bioactive compounds [21,22], and these
include the so-called standard markers such as phenolic
caffeic acid derivatives, alkylamides, and polysaccharides,
all of which have been proposed to be responsible for the
purported medical benefits of various Echinacea species
extracts [29]. However our recent studies on different
types of Echinacea extract suggest that specific bioactivities
may not be attributed to a single component. In addition
EF, like other Echinacea-derived extracts, contains numer-
ous other bioactive compounds such as flavonoids and
alkaloids [29], and it is conceivable that the key to the rel-
atively high potency of EF is the particular combination or
balance of individual ingredients.
Recent studies on the Mediterranean herb Cistus incanus
(rock rose) provide some interesting comparisons. Thus a
polyphenol-rich  Cistus  extract showed similar anti-IV
activities to those described in this report, suggesting a
similar mode of action [18]. The mechanism of Cistus
anti-viral activity was not elucidated however, so a com-
parative study of these two extracts could be useful and
provide interesting implications for the design of effective
anti-IV compounds.
In contrast, the study of Palamara et al [16] showed that
an individual polyphenol, resveratrol, a common constit-
uent of red grapes and various other plants, could inhibit
IV replication by interfering with signaling pathways
involved in viral RNP translocation. Thus an appropriate
combination of plant polyphenols could provide a multi-
functional approach to the control of influenza virus rep-
lication and its associated symptoms.
Conclusion
The data presented in this work have shown that a stand-
ardized preparation of Echinacae  has the potential to
impair influenza virus propagation, including seasonal
strains and strains of highly pathogenic avian influenza
viruses as well as the new pandemic strain of swine origin
at concentrations recommended for oral use and below.
Furthermore the preparation does not induce emergence
of resistant virus variants and is still active against strains
that have become resistant to treatment with neuramini-
dase inhibitors. This potential, the availability and the
lack of toxicity make this preparation an interesting
option in the control and treatment of influenza virus
infections
Methods
Standard Echinacea Preparation
Echinaforce® (obtained from A. Vogel Bioforce AG, Rog-
gwil, Switzerland) is a standardized preparation derived
by ethanol extraction of freshly harvested Echinacea purpu-
rea  herb and roots (95:5). The composition of marker
compounds (ie. those compounds known to characterize
this species of Echinacea) was described previously [21].
The concentration of ethanol was 65% v/v. The final con-
centration of ethanol in the experimental reactions and
cultures was too low to cause adverse effects on the cells
or viruses. In addition the preparation was free of detecta-
ble endotoxin (as determined by means of a commercial
assay kit, Lonza Walkersville Inc., MD, lower limit of
detection 0.1 unit/ml), and the administered amount that
was effective in our experiments, up to the recommended
oral dose of 1.6 mg/ml, was not cytotoxic according to
trypan blue staining, MTT formazan assays (MTT = 1-(4,5-
dimethylthiazol-2-yl)-3,5-diphenylformazan), and
microscopic examination [[21], and data not shown].
Cell lines & Viruses
Madin-Darby canine kidney cells (MDCK) were acquired
originally from ATCC and were passaged in Dulbecco's
MEM (DMEM), in cell culture flasks, supplemented with
5-10% fetal bovine serum, at 37°C in a 5% CO2 atmos-
phere (cell culture reagents were obtained from Invitro-
gen, Ontario (CA) or Karlsruhe (DE)). No antibiotics or
anti-mycotic agents were used for experiments performed
in the Hudson laboratory. In the Pleschka laboratory the
cell cultures were also grown in DMEM, 10% FCS but sup-
plemented by 100 U/ml penicillin and 100 μg/ml strepto-
mycin (P/S).
EF treatment does not select for resistant IV variants Figure 5
EF treatment does not select for resistant IV vari-
ants. MDCK cells were infected with KAN-1 (MOI = 0.001) 
and incubated 24 hours either with media without EF (black 
bars), or containing EF (50 μg/ml hatched bars) or Tamiflu® 
(2 μM, grey bars). Supernatant was titrated by FFU assay and 
used for a second round of infection of fresh MDCK cells. 
Three passages (1st, 2nd, 3rd round) were performed and 
after each the virus titer (FFU/ml) was determined by FFU 
assay. FFU titres of EF- and Tamiflu®-treated samples were 
calculated as percentage of controls set at 100%. Shown is 
the mean of duplicate experiments titrated in duplicates.
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The following influenza A virus strains were used: human
strain A/Victoria/3/75 (Victoria, H3N2) acquired from the
BC Centre for Disease Control, Vancouver. The human
HPAIV isolate A/Thailand/KAN-1/2004 (KAN-1, H5N1)
was provided to S. Pleschka by P. Puthavathana, Thailand;
the HPAIV A/FPV/Bratislava/79 (FPV, H7N7) and the
human strain A/Puerto Rico/8/34 (PR8, H1N1) were
obtained from the IV strain collection in Giessen, Ger-
many; the human isolate of the 2009 pandemic IV of
swine-origin A/Hamburg/1/09 (S-OIV, H1N1) was pro-
vided to S. Pleschka by M. Matrosovich, Marburg, Ger-
many. KAN-1 and FPV or PR8 were propagated on MDCK
cells with low serum but without trypsin (KAN-1, FPV) or
in embryonated chicken eggs (PR8), respectively. All other
strains were propagated on MDCK cells in the presence of
trypsin (2.5 μg/ml). Stock viruses were prepared as clari-
fied cell-free supernatants or allantois fluid, respectively,
with titers ranging from 107 to 108 PFU (plaque-forming
units) per ml. and stored at -75°C. Strains were titrated
either by standard plaque assay or by focus forming assays
(see below).
MIC100 values
MIC100 values of EF were determined from CPE-endpoint
assays, as follows: The Echinacea extract, in 200 μl aliq-
uots, was serially diluted two-fold across replicate rows of
a 96-well tray, in medium, starting at the recommended
oral dose of 1.6 mg/ml. Virus, 100 PFU in 100 μl, was
added to each well and allowed to interact with the extract
for 60 min at 22°C. Following the incubation period, the
mixtures were transferred to another tray of cells from
which the medium had been aspirated. These trays were
then incubated at 37°C, 5% CO2 until viral CPE were
complete in control wells containing untreated virus (usu-
ally 2 days). Additional wells contained cells not exposed
to virus. The MIC100 was the maximum dilution at which
CPE was completely inhibited by the extract. In most
assays the replicate rows gave identical end-points; when
two-fold differences were encountered arithmetic means
and standard deviations were calculated. In the alternative
(intra-cellular) method, the cells were incubated with the
diluted extracts first, before adding virus.
Virus titrations
Strain Victoria (H3N2) was titrated by standard plaque
assay techniques in MDCK cells with agarose overlays. The
other strains were assayed by focus formation in MDCK
cells as follows: Cells were grown overnight (to 90% con-
fluency) in complete medium in 96-well trays, washed
and inoculated with 50 μl of serially diluted (10-1 to 10-8)
virus in PBS containing 0.2% BA, 1 mM MgCl2, 0.9 mM
CaCl2, 100 U/ml penicillin and 0.1 mg/ml streptomycin
(PBS/BA), for 60 min at room temperature. The inoculum
was replaced by 150 μl MC media (1× DMEM, BA, P/S,
1.5% methyl cellulose). Cells were incubated at 37°C, 5%
CO2 for 44 hours. To detect foci of infection the cells were
permeabilized with 330 μl fixing solution (4% parafor-
maldehyde, 1% triton X-100, in PBS) and stored at 4°C
for 60 min followed by 3 washes with PBS/0.05% Tween
20, and incubation with 50 μl 1st antibody (mouse anti-
influenza A nucleoprotein mAb, BIOZOL BZL 10908)
diluted in PBS/3% BA at room temperature for 60 min.
Cells were then washed 3 × with PBS/Tween 20 and incu-
bated with 2nd antibody (anti-mouse HRP antibody Santa
Cruz sc2005) diluted in PBS/3% BA at room temperature
for 60 min. Finally cells were washed 3 × with PBS/
Tween20 and incubated in 40 μl AEC staining solution (3-
amino-9-ethylcarbazole, Sigma Chemical, AEC #101) for
60 min followed by washing in dH2O. Foci were scanned
and analyzed by means of Photoshop software (Adobe).
All titrations were performed in duplicate.
Pre-incubations
In some experiments aliquots of virus (H3N2 or H5N1) in
PBS/BA or the cells in complete medium, were pre-incu-
bated with EF (50 μg/ml) at room temperature or 37°C
respectively for 60 min, prior to infection. Infected cells
and controls were then incubated in medium containing
EF (50 μg/ml) at 37°C, 5% CO2 for 24 hours, at which
time supernatants were removed for focus assays.
Intra-cellular RNP localization
Cells were grown and infected on cover slips, and pre-
incubations of the viruses were carried out as described
above. Cells were fixed, at different times post infection
(p.i.), washed with PBS and incubated with 1st antibody,
as described above (2.4). Incubation with 2nd antibody
(rabbit anti-mouse Texas red) diluted in PBS/3%BA was
carried out at room temperature for 60 min in the dark.
Cells were washed again and incubated with DAPI (0.1
mg/ml PBS/3%BA, Roth Germany) for 10 min in the dark
to stain nuclei. After further washing the cover slips with
cells were covered with Moviol + DABCO (Moviol,
Aldrich, glycerine, Merck, ddH2O, Tris-Cl pH 8.5 + 1,4-
Diazobicyclo [2.2.2]octane, Merck) on glass slides. Cells
were examined and digitized with a TCS SP5 confocal
laser scanning microscope (Leica, Germany).
Hemagglutination assay
25  μl EF in PBS at the indicated concentrations were
added to wells of a 96-well tray. Thereafter 25 μl of virus
with ca. 2560 HAU/ml were added. The plates were incu-
bated for 60 min at 4°C. After this incubation period, 50
μl of chicken erythrocyte suspension (CES, 0.5% in PBS)
were added to each well. The plates were further incubated
for 60 min or 4 hours at 4°C. Wells were visually
inspected for the presence or absence of hemagglutina-
tion. Positive and negative controls without EF treatment
or without virus were included. To assay possible hemag-
glutination by EF itself, 50 μl of EF in PBS at the indicatedVirology Journal 2009, 6:197 http://www.virologyj.com/content/6/1/197
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concentrations were incubated with 50 μl CES for 60 min
or 4 hours at 4°C. All assays were performed in quadrupli-
cate.
Virus Resistance Assay
MDCK cells grown over night at 37°C and 5% CO2 were
pre-incubated with 2 ml complete medium (1× DMEM,
10% FCS, Pen/Strep) with or without EF (50 μg/ml), at
37°C and 5% CO2 for 60 min. In parallel virus in PBS/BA
was incubated with EF (50 μg/ml) or left untreated for 60
min. After the pre-incubation period the cells were
washed and infected with 500 μl virus suspension (MOI =
0,001) (+/-) Echinaforce® (50  μg/ml). Cells were then
incubated for 60 min in the dark at room temperature
after which the inoculum was removed. Cells were further
incubated in 2 ml medium (DMEM/BA/P/S with Echina-
force® (50 μg/ml), Tamiflu® (2 μM) or without test sub-
stances) at 37°C, 5% CO2 for 24 hours. Samples of the
supernatants were collected, which were then assayed by
focus forming assay for further determination of infec-
tious virus. Following the assays, these supernatants were
used to infect another set of cultures under the same con-
ditions as described above. This process of sequential
infection with supernatants was repeated once more to
yield in total three rounds of infection and replication.
Experiments done in duplicates were stopped when the
Tamiflu® sample reached titers of the untreated control.
Biosafety
All experiments with infectious virus were performed
according to German and Canadian regulations for the
propagation of influenza A viruses. All experiments
involving highly pathogenic influenza A viruses and the
pandemic S-OIV were performed in a biosafety level 3
(BSL3) containment laboratory approved for such use by
the local authorities (RP, Giessen, Germany).
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